Detalhe da pesquisa
1.
A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
J Immunol
; 210(12): 2029-2037, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163328
2.
Immune resilience in response to cancer therapy.
Cancer Immunol Immunother
; 69(11): 2165-2167, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33011909
3.
Resilient T-cell responses in patients with advanced cancers.
Int J Hematol
; 117(5): 634-639, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35864292
4.
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors.
Immunohorizons
; 7(1): 125-139, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36656137
5.
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation.
Sci Adv
; 9(46): eadi2414, 2023 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37967193
6.
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Cancer Immunol Res
; 10(2): 162-181, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911739
7.
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Front Immunol
; 11: 580328, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33384686
8.
Paradox-driven adventures in the development of cancer immunology and immunotherapy.
Genes Dis
; 6(3): 224-231, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32042862
9.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Cancer Immunol Res
; 7(1): 100-112, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30396908